** Shares of drug developer Compass Therapeutics CMPX.O fall 14.5% to $1.62
** CMPX says its experimental biliary tract cancer drug, tovecimig, when combined with chemotherapy, showed an overall response rate $(ORR.AU)$ of 17.1% in patients compared to 5.3% who received chemotherapy alone
** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined period of time
** Brokerage Leerink Partners says this response rate is lower than expected, and lower than what was seen in previous trials
** Other treatments, such as Enhertu by AstraZeneca AZN.L and Pemazyre by Incyte INCY.O, have shown higher response rates in similar patient populations, brokerage says
** Including sessions moves, CMPX stock up 31% YTD
(Reporting by Padmanabhan Ananthan)
((padmanabhan.ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。